Modality
Degrader
MOA
SOS1i
Target
BTK
Pathway
DDR
MDS
Development Pipeline
Preclinical
May 2017
→ Jul 2025
PreclinicalCurrent
NCT05080214
2,190 pts·MDS
2017-05→2025-07·Terminated
2,190 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-07-188mo agoInterim· MDS
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3
Preclinical
Termina…
Catalysts
Interim
2025-07-18 · 8mo ago
MDS
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05080214 | Preclinical | MDS | Terminated | 2190 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| RHH-8482 | Roche | Phase 1 | BTK | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| REG-647 | Regeneron | Preclinical | SMN2 |